Edwards Lifesciences Corporation

Edwards Lifesciences Corporation

EW

$95.19

Updated: 04/11/2026, 00:58:36

Market Cap
$54.87B
Sector
Healthcare
Industry
Medical - Devices
Country
US

No historical data available

Company Profile

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

USD
NYSE
CEO: Bernard J. Zovighian
Employees: 16,000
https://www.edwards.com
Asset Summaries
Latest generated summaries for EW

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
EW-10-k-fy2025.html2.9 MBtext/htmlENFiled 25/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 64 KPI observations

Revenue

$6.1B

FY 2025 · Reported

Net income

$1.1B

FY 2025 · Reported

Gross margin

78.0%

FY 2025 · Calculated

Free cash flow

$1.3B

FY 2025 · Calculated

R&D intensity

17.8%

FY 2025 · Calculated

Share repurchases

$0.9B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

TAVR — SAPIEN valve family
TMTT portfolio — PASCAL, EVOQUE, SAPIEN M3
Pericardial tissue valves identified as product family
Surgical Structural Heart portfolio
2025 regulatory approvals and launches

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureUnited States: 58.4% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 25.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 25.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 25.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 25.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureEurope: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureEurope: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureJapan: 5.8% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 25.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)Europe: 25.0% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

Revenue exposure by reported geography
FY 2025 share of total net sales. Regional segments are kept as regions rather than falsely allocated to individual countries.
United States
+58.4%
Europe
+25.0%
Other markets
+10.8%
Japan
+5.8%

How the business makes money

Company overview

Leading global structural heart disease innovation company, managed in US, Europe, Japan, Rest of World; products: TAVR, TMTT, Surgical

98%
Source evidence
“We are the leading global structural heart disease innovation company, driven by a passion to improve patient lives.”

Company overview

Leading global structural heart innovation company, Irvine, CA

98%
Source evidence
“Edwards Lifesciences Corporation is the leading global structural heart innovation company”

Customer types

Hospitals, clinicians, purchasing decision makers, and ministries of health

93%
Source evidence
“our customers include decision makers such as service line leaders, material managers, biomedical staff, hospital administrators and executives, purchasing managers, and ministries of health”

Distribution model

Direct sales forces plus independent distributors; GPO and IDN contracts in US/Europe

94%
Source evidence
“our distribution system consists of several direct sales forces as well as independent distributors”

TAVR — SAPIEN valve family

SAPIEN family TAVR valves; 15+ years trials, 1.2M patients treated

97%
Source evidence
“SAPIEN is the most studied valve in the world, with more than 15 years of distinguished clinical trials involving over 10,000 patients, 10 New England Journal of Medicine publications and 1.2 million patients treated around the world.”

TMTT portfolio — PASCAL, EVOQUE, SAPIEN M3

PASCAL repair (EU/US/JP), EVOQUE TR replacement (EU/US), SAPIEN M3 TMVR (EU/US)

96%
Source evidence
“The EVOQUE system, the world's first transcatheter tricuspid valve replacement therapy to receive regulatory approval”

Pericardial tissue valves identified as product family

Pericardial tissue valves are manufactured using bovine tissue.

95%
Source evidence
“The bovine tissue used in our pericardial tissue valves is from tissue types considered by global health and regulatory organizations to have shown no risk of infectibility for the suspected BSE infectious agent.”

Surgical Structural Heart portfolio

INSPIRIS, KONECT, MITRIS RESILIA valves; RESILIA tissue >99% freedom from SVD at 8 years

95%
Source evidence
“Our differentiated RESILIA tissue technology, with published clinical data showing over 99% freedom from structural valve deterioration through eight years”

2025 regulatory approvals and launches

FDA approval SAPIEN 3 for asymptomatic severe AS; FDA/CE Mark SAPIEN M3 mitral replacement; CE Mark KONECT RESILIA aortic valved conduit

95%
Source evidence
“we received FDA and CE Mark approval for the SAPIEN M3 mitral valve replacement system, launching in both Europe and the U.S.”

Net sales by geographic region 2025 vs 2024

US $3,543.1M (+10.5%), Europe $1,517.5M (+14.8%), Japan $354.7M (+4.4%), RoW $652.3M (+14.0%), total $6,067.6M (+11.5%)

99%
Source evidence
“United States$3,543.1 $3,206.0 $337.1 10.5 %”

Net sales by product group 2025 vs 2024

TAVR $4,487.7M (+9.3%), TMTT $550.6M (+56.4%), Surgical $1,029.3M (+4.9%), total $6,067.6M (+11.5%)

99%
Source evidence
“Transcatheter Aortic Valve Replacement$4,487.7 $4,106.1 $381.6 9.3 %”

Net sales by product group, 2023-2025

TAVR 74%/75%/77%; TMTT 9%/7%/4%; Surgical 17%/18%/19% of net sales in 2025/2024/2023

98%
Source evidence
“Sales of our TAVR products represented 74%, 75%, and 77% of our net sales in 2025, 2024, and 2023, respectively.”

Operations and dependencies

Bovine tissue sourcing for tissue valves

Pericardial tissue valves use bovine tissue sourced only from closely controlled sources in the US and Australia.

98%
Source evidence
“We obtain bovine tissue only from closely controlled sources within the United States and Australia.”

Single-source supplier reliance

Single-source suppliers for certain supplies and services; hard to replace under FDA rules

95%
Source evidence
“we purchase certain supplies and services from single sources for reasons of quality assurance, cost-effectiveness, availability, constraints resulting from regulatory requirements, and other reasons”

Headcount and labor representation

~16,000 employees worldwide, majority in US, Singapore, Costa Rica; no unionized North American employees

96%
Source evidence
“As of December 31, 2025, we had approximately 16,000 employees worldwide, the majority of whom were located in the United States, Singapore, and Costa Rica.”

Positioning and strategy

Vectorious noncontrolling interest buyout

Acquired remaining Vectorious stake for $233.7M, ownership 61%→100%

95%
Source evidence
“the Company acquired the remaining noncontrolling interest of Vectorious for $233.7 million, increasing the Company's total ownership from 61% to 100%.”

Innovalve Bio Medical acquisition (2024)

Innovalve acquired Oct 1, 2024; total price $402.0M ($380.9M net of cash); goodwill $205.4M; IPR&D $218.4M

95%
Source evidence
“The purchase consideration for the acquisition of Innovalve was $380.9 million”

Primary competitors

Medtronic and Abbott are primary competitors across TAVR, TMTT and Surgical

96%
Source evidence
“In TAVR, our primary competitors include Medtronic plc ("Medtronic") and Abbott Laboratories ("Abbott"). In TMTT, our primary competitor is Abbott”

Cardiovascular disease burden drives demand

CVD is world's #1 cause of death; progressive disease with expansion into heart failure

93%
Source evidence
“Cardiovascular disease is the number-one cause of death in the world and is the top disease in terms of health care spending in nearly every country.”

Sale of non-core product group and Critical Care

Completed sale of non-core product group Dec 18, 2025; Critical Care sold to BD Sep 3, 2024; both as discontinued operations

98%
Source evidence
“On September 3, 2024, we sold our Critical Care product group ("Critical Care") to Becton, Dickinson and Company ("BD").”

TAVR and TMTT demand drivers

TAVR growth from SAPIEN 3 Ultra RESILIA (US/Europe); TMTT from PASCAL and EVOQUE; FX added $26.7M

95%
Source evidence
“higher sales of our PASCAL transcatheter edge-to-edge repair system and EVOQUE tricuspid valve replacement system in the United States and Europe”

TMTT growth

TMTT sales share nearly doubled to 9% of net sales in 2025 from 4% in 2023

92%
Source evidence
“Sales of our TMTT products represented 9%, 7%, and 4% of our net sales in 2025, 2024, and 2023, respectively.”

R&D investment 18% of net sales

Invested 18% of net sales in R&D in 2025; increases driven by implantable heart failure management innovations

95%
Source evidence
“In 2025, we invested 18% of our net sales in research and development.”

Strategy of innovation, evidence, and indication expansion

Differentiated innovation, world-class evidence generation and indication expansion

94%
Source evidence
“Edwards' leadership strategy of differentiated innovation, world-class evidence generation and indication expansion is driving guideline and policy evolution and improved patient access and long-term adoption of the SAPIEN platform.”

Vision to expand into non-valvular structural heart disease

Growth vision: valvular plus non-valvular structural heart disease (heart failure); broad clinical evidence generation

92%
Source evidence
“Our vision for growth is to treat patients with both valvular and non-valvular structural heart disease, such as heart failure”

Risks, financing, and outlook

Data privacy and security laws (HIPAA, GDPR, CCPA/CPRA)

Compliance with HIPAA, GDPR, CCPA/CPRA and evolving privacy laws imposes substantial requirements; GDPR provides significant penalties and CCPA/CPRA a private right of action.

92%
Source evidence
“The GDPR imposes stringent EU data protection requirements and provides for significant penalties for noncompliance.”

Healthcare pricing, anti-kickback, and fraud-and-abuse laws

Subject to global US and foreign healthcare pricing, anti-competition, anti-corruption, anti-kickback, and false claims laws; violations may bring fines, imprisonment, and exclusion from governmental healthcare programs.

90%
Source evidence
“we and our suppliers are subject to various United States and foreign laws pertaining to health care pricing, anti-competition, anti-corruption, and fraud and abuse, including prohibitions on kickbacks and the submission of false claims laws”

Environmental, health, and safety regulation costs

Operations subject to environmental, health, and safety laws on hazardous waste, cleanup, and emissions; stricter enforcement or new laws could require material costs.

85%
Source evidence
“New laws and regulations, violations of these laws or regulations, stricter enforcement of existing requirements, or the discovery of previously unknown contamination could require us to incur costs or could become the basis for litigation or new or increased liabilities that could be material.”

Innovation risk

Product innovation and marketing failure risk

98%
Source evidence
“Failure to successfully innovate and develop new and differentiated products in a timely manner and effectively market these products could have a material effect on our prospects.”

Clinical trial risk

Clinical trials inherently uncertain; unfavorable data could block approvals

98%
Source evidence
“Unsuccessful clinical trials or procedures relating to products could have a material adverse effect on our prospects.”

Competition risk

Constrained procedure volumes as products compete for same hospital facilities and staffing

95%
Source evidence
“We have in the past and are continuing to experience constrained procedure volumes and sales for our products because more products, including Edwards’ own products, are competing for the same facilities and staffing within hospitals.”

Dependence on key physicians and hospital systems

Dependence on key physicians, research institutions, hospital cath labs

95%
Source evidence
“a decision by a hospital system, particularly a large hospital system, not to adequately staff or provide facilities necessary to perform procedures using our products, or a decision to use a competitors’ products instead of ours, has in the past and may continue in the future to meaningfully adversely impact our ability to sell our products”

Critical Care divestiture risk

Risks related to sale of Critical Care product group

95%
Source evidence
“Risks associated with the sale of our Critical Care product group”

Reimbursement risk

Reimbursement risk incl. restrictive U.S. NCD for TAVR procedures

95%
Source evidence
“restrictive requirements in the U.S. national coverage determination for transcatheter aortic valve replacement procedures”

Animal-borne illness (BSE) risk for bovine-based products

BSE concerns could reduce acceptance of bovine-tissue products; no significant adverse sales impact experienced so far.

95%
Source evidence
“Concerns relating to the potential transmission of animal-borne illnesses, including BSE, commonly known as "mad cow disease," from cows to humans may result in reduced acceptance of products containing bovine materials.”

Manufacturing/quality risk

Complex manufacture and sterilization; recalls and approvals delays possible

95%
Source evidence
“If we or one of our suppliers or logistics partners encounters manufacturing, logistics, safety, or quality problems, our business could be materially adversely affected.”

Competitive/technological obsolescence risk

Obsolescence risk from technological advances and alternative drug therapies

93%
Source evidence
“Our present or future products could be rendered obsolete or uneconomical as a result of technological advances by one or more of our present or future competitors or by other therapies, including drug therapies.”

Health care regulation risk

Health care legislation and government regulation compliance risk

90%
Source evidence
“Reduced access and demand for our products as a result of, and compliance with, health care legislation and other government regulations”

IP risk

IP protection and third-party IP claim risks

90%
Source evidence
“Inability to protect our intellectual property; Inability to defend against intellectual property claims from third parties”

Cybersecurity/IT risk

IT system damage and cybersecurity attack risk

90%
Source evidence
“Damage, failure, or interruption of our information technology systems, including due to cybersecurity attacks and breaches”

Public health crisis risk

Public health crises including pandemics and epidemics

90%
Source evidence
“We are subject to risks associated with public health crises, including pandemics and epidemics”

Emerging technologies/AI risk

AI and emerging technology adoption risk

90%
Source evidence
“Our use of, or our failure to effectively and timely utilize, emerging technologies, including AI, could adversely impact our business and financial results.”

Product portfolio mentioned in risks

TAVR and TMTT product groups referenced in hospital capacity risk

85%
Source evidence
“including technologies we develop and introduce in both our TAVR and TMTT product groups”

Effective tax rate fluctuation drivers

Effective tax rate may fluctuate due to earnings mix across jurisdictions, stock comp benefits, credits, deferred tax valuations, withholding taxes, and acquisitions.

85%
Source evidence
“Our provision for income taxes and our effective tax rate could fluctuate due to changes in the mix of earnings and losses in countries with differing statutory tax rates.”

Climate change physical and regulatory risks

Extreme weather could disrupt facilities, supply chain, and raw material availability; climate regulation could raise compliance costs across sourcing, manufacturing, and distribution.

85%
Source evidence
“Such extreme weather conditions could pose physical risks to our facilities and disrupt operation of our supply chain and may impact operational costs and could have an adverse impact on the availability of raw materials.”

Off-label use of products could create liability

Products approved for limited indications may be used by physicians in unapproved circumstances, exposing the company to claims.

85%
Source evidence
“Physicians, however, can use these products in ways or circumstances other than those strictly within the scope of the regulatory approval.”

Third-party data processing risk

Relies on third parties to host/process personal data; their failure to comply with privacy laws could materially harm the business.

80%
Source evidence
“We also rely on third parties to host or otherwise process some of this data, who are subject to similar risks”

Material exposure graph

TAVR (SAPIEN family)
Revenue Exposure

TAVR is the dominant revenue driver at 74% of 2025 net sales, down modestly from 77% in 2023

Relevance 98·Dependency 85·Confidence 98
Source evidence
“Sales of our TAVR products represented 74%, 75%, and 77% of our net sales in 2025, 2024, and 2023, respectively.”
Edwards SAPIEN 3 Ultra RESILIA valve
Revenue Exposure

TAVR, the largest product group at $4.5B, grew primarily on SAPIEN 3 Ultra RESILIA sales in the US and Europe.

Relevance 95·Dependency 85·Confidence 95
Source evidence
“primarily due to higher sales of the Edwards SAPIEN 3 Ultra RESILIA valve in the United States and Europe”
Hospital systems
Customer Exposure

Sales depend on hospital systems adequately staffing catheterization laboratories; large hospital decisions have meaningfully adversely impacted sales.

Relevance 85·Dependency 80·Confidence 90
Source evidence
“we rely on hospital systems to be able to hire staff and have available facilities, including catheterization laboratories, to perform procedures using our products”
bovine tissue
Raw Material Dependency

Pericardial tissue valves depend on bovine tissue sourced only from closely controlled US and Australian suppliers; BSE concerns or supply disruption would directly affect tissue valve products.

Relevance 85·Dependency 70·Confidence 95
Source evidence
“We obtain bovine tissue only from closely controlled sources within the United States and Australia.”
EVOQUE tricuspid valve replacement system
Revenue Exposure

TMTT's 56.4% growth was driven by PASCAL and EVOQUE sales in the US and Europe.

Relevance 85·Dependency 60·Confidence 93
Source evidence
“higher sales of our PASCAL transcatheter edge-to-edge repair system and EVOQUE tricuspid valve replacement system in the United States and Europe”
Medtronic plc
Competitive Exposure

Medtronic is a primary competitor in both TAVR and Surgical product lines

Relevance 85·Dependency 40·Confidence 95
Source evidence
“In TAVR, our primary competitors include Medtronic plc ("Medtronic") and Abbott Laboratories ("Abbott").”
Abbott Laboratories
Competitive Exposure

Abbott is a primary competitor in TAVR, the sole named primary competitor in TMTT, and a primary competitor in Surgical

Relevance 85·Dependency 40·Confidence 95
Source evidence
“In TMTT, our primary competitor is Abbott”
U.S. national coverage determination for TAVR
Demand Driver

Restrictive U.S. NCD requirements for TAVR procedures can limit marketing success and procedure volumes.

Relevance 80·Dependency 70·Confidence 90
Source evidence
“restrictive requirements in the U.S. national coverage determination for transcatheter aortic valve replacement procedures”
FDA and other regulatory authorities
Legal Exposure

Manufacture and sterilization are highly complex due to rigorous regulatory requirements; supplier changes require significant effort under FDA rules.

Relevance 80·Dependency 70·Confidence 90
Source evidence
“A change or addition to our vendors could require significant effort due to the rigorous regulations and requirements of the FDA and other regulatory authorities”
Cardiovascular disease burden
Demand Driver

Progressive cardiovascular disease, the world's number-one cause of death, underpins demand for structural heart therapies and future growth in heart failure treatment

Relevance 80·Dependency 60·Confidence 90
Source evidence
“Cardiovascular disease is the number-one cause of death in the world and is the top disease in terms of health care spending in nearly every country.”
Single-source suppliers
Supplier Dependency

Certain supplies and services are purchased from single sources; replacing vendors is difficult under FDA regulations, creating supply interruption risk.

Relevance 75·Dependency 70·Confidence 90
Source evidence
“we purchase certain supplies and services from single sources for reasons of quality assurance, cost-effectiveness, availability, constraints resulting from regulatory requirements, and other reasons”
Hospital facilities and staffing capacity
Competitive Exposure

Multiple new technologies including Edwards' own TAVR and TMTT products compete for the same hospital facilities and staffing, constraining procedure volumes and sales.

Relevance 75·Dependency 65·Confidence 85
Source evidence
“more products, including Edwards’ own products, are competing for the same facilities and staffing within hospitals”
long-term implantable devices
Legal Exposure

Long-term implantable devices expose the company to product liability claims that may exceed insurance coverage limits.

Relevance 75·Dependency 50·Confidence 90
Source evidence
“product liability or other claims may exceed insurance coverage limits, fines, and penalties”
TMTT (PASCAL/EVOQUE/SAPIEN M3)
Revenue Exposure

TMTT is the fastest-growing product group, rising from 4% to 9% of net sales between 2023 and 2025

Relevance 75·Dependency 35·Confidence 95
Source evidence
“Sales of our TMTT products represented 9%, 7%, and 4% of our net sales in 2025, 2024, and 2023, respectively.”
Healthcare reimbursement and regulatory approval systems
Regulatory Exposure

Where Edwards markets products is influenced by existence of, or potential for, adequate reimbursement by national healthcare systems; approvals and adoption depend on clinical evidence

Relevance 70·Dependency 60·Confidence 85
Source evidence
“Where we choose to market our products is also influenced by the existence of, or potential for, adequate reimbursement to hospitals and other providers by national healthcare systems.”
Direct sales forces and independent distributors
Customer Exposure

Sales reach hospitals worldwide via direct sales forces and independent distributors, supplemented by GPO and national/regional buying group contracts

Relevance 70·Dependency 55·Confidence 93
Source evidence
“our distribution system consists of several direct sales forces as well as independent distributors”
OECD Pillar Two global minimum tax
Tax Exposure

Pillar Two 15% global minimum tax added ~$19.1M of tax expense in 2025 and raised the effective tax rate to 17.0%; ongoing enactment risk remains.

Relevance 70·Dependency 50·Confidence 93
Source evidence
“Many countries are implementing some or all of the Organisation for Economic Co-operation and Development's Base Erosion and Profit Shifting Pillar Two ("Pillar Two") rules that impose a global minimum tax of 15% on reported profits”
Euro
Currency Exposure

Euro strengthening against USD increased non-US net sales by $26.7 million in 2025; FX also affects international manufacturing and operating costs, partially hedged.

Relevance 70·Dependency 40·Confidence 92
Source evidence
“foreign currency exchange rate fluctuations increased net sales outside of the United States by $26.7 million primarily due to the strengthening of the Euro against the United States dollar”
Surgical Structural Heart
Revenue Exposure

Surgical tissue heart valves contributed 17% of 2025 net sales (18% in 2024, 19% in 2023)

Relevance 70·Dependency 30·Confidence 95
Source evidence
“Sales of our surgical tissue heart valve products represented 17%, 18%, and 19% of our net sales in 2025, 2024, and 2023, respectively.”
Raw material cost increases/inflation
Cost Driver

Significant raw material cost increases from inflationary pressure, supply constraints, tariffs, or regulatory changes could adversely impact operating results.

Relevance 65·Dependency 50·Confidence 85
Source evidence
“any significant increases in the cost of raw materials, whether due to inflationary pressure, supply constraints, the imposition of tariffs, regulatory changes, or otherwise, could adversely impact our operating results”
US and foreign healthcare fraud and abuse laws
Regulatory Exposure

Anti-kickback, false claims, and physician-relationship restrictions affect sales practices; violations risk fines, imprisonment, and exclusion from governmental healthcare programs.

Relevance 65·Dependency 40·Confidence 90
Source evidence
“Any alleged or actual violations of these laws may subject us to government investigations and significant criminal or civil sanctions and may impact our ability to sell products in certain jurisdictions”
OECD Pillar Two
Regulatory Exposure

Pillar Two implementation and the treatment of the U.S. tax regime as a qualified side-by-side system could materially impact the tax provision.

Relevance 60·Dependency 45·Confidence 90
Source evidence
“could impact our provision for income taxes”
Artificial intelligence (AI)
Technology Dependency

Edwards uses AI and emerging technologies in various facets of operations; failure to effectively and timely utilize them could adversely impact results.

Relevance 55·Dependency 45·Confidence 85
Source evidence
“We use AI and other emerging technologies in various facets of our operations and our business.”
Australia
Revenue Exposure

Australia is one of only two disclosed sources (with the US) of bovine tissue used in pericardial tissue valves.

Relevance 55·Dependency 40·Confidence 85
Source evidence
“We obtain bovine tissue only from closely controlled sources within the United States and Australia.”
United States
Supplier Dependency

The United States is one of only two disclosed sources of bovine tissue used in pericardial tissue valves.

Relevance 55·Dependency 40·Confidence 85
Source evidence
“We obtain bovine tissue only from closely controlled sources within the United States and Australia.”
FTC / Hart Scott Rodino
Legal Exposure

Company accrued a payment and agreed to conditions to resolve an FTC dispute over failure to file an HSR notice for the JC Medical acquisition.

Relevance 55·Dependency 30·Confidence 85
Source evidence
“the Company has accrued for a payment and has agreed to certain other conditions to resolve a dispute with the FTC regarding its decision not to file a Hart Scott Rodino notice for its acquisition of JC Medical, Inc.”
GDPR
Regulatory Exposure

GDPR imposes stringent EU data protection requirements with significant penalties for noncompliance on processing of patient and customer data.

Relevance 50·Dependency 35·Confidence 90
Source evidence
“The GDPR imposes stringent EU data protection requirements and provides for significant penalties for noncompliance.”
Full company information
Latest profile, trading, valuation, and identifier data stored for EW.
Share price
$95.19
Market cap
$54.87B
Exchange
NYSE
Currency
USD
CEO
Bernard J. Zovighian
Employees
16,000
IPO date
27/03/2000
Beta
0.846
Last dividend
$0.00
Day range
$93.27 – $96.09
52-week range
$74.66 – $96.29
1-day performance
2.07%
1-year performance
27.50%
Current drawdown (1Y)
-1.14%
CIK
0001099800
CUSIP
28176E108
ISIN
US28176E1082
Created
07/12/2025, 03:52:41
Last update
04/11/2026, 00:58:36

Track Edwards Lifesciences Corporation with an AI analyst

See which prediction-market events move EW, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to EW from your Railway `news_articles` table.